Zydus Receives Final Approval from the US FDA for Valsartan and Hydrochlorothiazide Tablets

Zydus Cadila has received the final approval from the US FDA to market Valsartan and Hydrochlorothiazide Tablets USP (US RLD – Diovan HCT Tablets) in the strengths of 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg. The drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has 256 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. – Medical Buyer Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.